Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...

Healthcare startup Capital Rx seeing revenue surge as Congress seeks to regulate the PBM giants that profit from high drug ...

Prescription drug prices in America remain higher than in any comparable nation. The ongoing lack of price and data transparency coupled with the obvious financial incentives for providers and others ...

The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future ...

The 340B Drug Pricing Program (340B Program) is no stranger to controversy. We have previously covered the ongoing contract pharmacy legal battles ...

Verona Pharma (NASDAQ:VRNA – Free Report) had its price target hoisted by Canaccord Genuity Group from $44.00 to $72.00 in a research note published on Wednesday,Benzinga reports. They currently have ...

The state refuted the argument that its prescription drug pricing transparency law compels pharmaceutical companies to disclose trade secrets.